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AIM
The overall aim of this project was to develop an evidence-
based clinical practice guideline for evaluation and manage-
ment of CKD. The guideline consists of recommendation
statements, rationales, and a summary of systematically
generated evidence on relevant pre-defined clinical topics. To
a large extent the guideline builds on the output of the
KDIGO Controversies Conference in 2009,30 which generated
epidemiological data to support a revision of the classifica-
tion and staging system. The vision for this KDIGO guideline
is that it would endorse the current CKD definition as an
imperfect convention for describing a state of function, revise
classification based on risk, revise risk states, and revise and
update action plans in view of the revised classifications.
Additional systematic evidence review focused on specific
topics.
OVERVIEW PROCESS
The guideline development process included the following steps:
K Appointing Work Group members and the ERT
K Discussing process, methods, and results
K Developing and refining topics
K Identifying populations, interventions or predictors, and
outcomes of interest
K Selecting topics for systematic evidence review
K Standardizing quality assessment methodology
K Developing and implementing literature-search strategies
K Screening abstracts and retrieving full text articles on the
basis of predefined eligibility criteria
K Creating data extraction forms
K Extracting data and performing critical appraisal of the
literature
K Grading the methodology and outcomes in individual
studies
K Tabulating data from individual studies into summary
tables
K Grading the strength of recommendations on the basis of
the quality of evidence and other considerations
K Finalizing guideline recommendations and supporting
rationales
K Sending the guideline draft for peer review to the KDIGO
Board of Directors in January 2012 and for public review
in May 2012
K Publishing the final version of the guideline
Collaboration Among Participants
The KDIGO Co-Chairs appointed the Work Group
Co-Chairs, who then assembled the Work Group of domain
experts, including individuals with expertise in internal
medicine, adult and pediatric nephrology, diabetology/
endocrinology, clinical chemistry, and epidemiology. The
Tufts Center for Kidney Disease Guideline Development and
Implementation at Tufts Medical Center in Boston, Massa-
chusetts, USA, was contracted to conduct systematic evidence
review and provide expertise in guideline development
methodology. The ERT consisted of physician–methodolo-
gists with expertise in nephrology, a project coordinator, a
research assistant, and a medical writer–editor. The ERT
instructed and advised Work Group members in all steps of
literature review, critical literature appraisal, and guideline
development. The Work Group and the ERT collaborated
closely throughout the project.
The Work Group and its Chairs, KDIGO Co-chairs, ERT,
and KDIGO support staff met for three 2-day meetings for
training in the guideline development process, topic discus-
sion, and consensus development.
Throughout the project, the ERT offered suggestions for
guideline development and led discussions on systematic
review, literature searches, data extraction, assessment of
quality and applicability of articles, evidence synthesis,
grading of evidence and guideline recommendations, and
consensus development. The Work Group took the primary
role of writing the recommendation statements and ratio-
nales and retained final responsibility for their content.
Defining Scope and Topics
This KDIGO CKD guideline was set out to update the
KDOQI Clinical Practice Guidelines for CKD: Evaluation,
Classification, and Stratification1 in 2002, which spans many
topics related to the diagnosis, classification, stratification,
and management of CKD.1
The Work Group Co-Chairs prepared the first draft of the
scope of work document as a series of open-ended questions
to be considered by Work Group members. At their first 2-
day meeting, members added further questions until the
initial working document included all topics of interest to the
Work Group. The inclusive, combined set of questions
formed the basis for the deliberation and discussion that
followed. The Work Group strove to ensure that all topics
deemed clinically relevant and worthy of review were
identified and addressed.
Updating the topics of definitions and classification was
based on the output from the KDIGO Controversies
Conference and the CKD Prognosis Consortium.4,30
Additional topics that relate to explicit selection of
diagnostic tests or interventions were chosen to undergo
systematic review of the best available evidence. Systematic
methods fo r gu ide l ine deve lopment http://www.kidney-international.org
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evidence review entails a priori question formulation,
specification of important outcomes for the review, systema-
tic searches, data extraction, tabulation, analysis, and
synthesis of evidence and is described in detail for each of
the specific questions. The process followed for each evidence
review topic (a total of four non-treatment topics and four
treatment topics) is detailed below.
The eight topics for which the ERT conducted searches
and evidence review are shown in Table 37. For the systematic
review topics, the Work Group and ERT further developed
and refined each topic and specified screening criteria,
literature search strategies, and data extraction forms.
Many other topics were not suitable to be addressed by in-
depth evidence review. When the anticipated outcome of an
extensive literature search was unlikely to yield evidence that
directly informs practice choices, the approach chosen was
that of a narrative review.
APPROACH TO EVIDENCE REVIEW TOPICS
Formulating Questions of Interest
Questions of interest were formulated according to the
PICODD (Population, Intervention or Predictor, Compara-
tor, Outcome, study Design, and Duration of follow-up)
criteria. Details of the PICODD criteria are presented in
Table 37.
Literature Searches and Article Selection for Evidence Review
Topics
Search strategies were developed by the ERT, with input from
the Work Group, for each topic of interest (whether
treatment or non-treatment topics). The ERT performed
literature searches and conducted abstract and article
screening. The ERT also coordinated the methodological
and analytic processes, data extraction, and summarizing of
the evidence. Before initiating our own de novo systematic
review, we searched for existing systematic reviews that could
be used. The searches and search terms are provided in
Supplemental Table 1 and the search dates and yields for all
topics are presented in Table 38.
Selection of Outcomes of Interest
The Work Group selected outcomes of interest on the basis of
their importance for informing clinical decision making.
Importance of mortality and ESRD was considered to be
critical; the importance of progression of CKD and
categorical or continuous measures of kidney function was
considered to be high; and the importance of QOL, BP, gout
attacks, and proteinuria was considered to be moderate.
Data Extraction
Text articles were extracted by the ERT onto forms
customized to capture data on design, methodology, baseline
characteristics, interventions or predictors, comparators,
outcomes, results, and limitations of individual studies.
Study methodology and risk of bias were also systematically
graded for each outcome and recorded.
Summary Tables
Pertinent information for systematic review topics was
tabulated in summary tables. Summary tables list out-
comes of interest as well as relevant population character-
istics, descriptions of interventions and comparators,
results, and quality grades for each outcome. Categorical
and continuous outcomes were summarized separately.
Work Group members reviewed all summary table data
and quality grades.
Evidence Profiles
Evidence profiles are usually constructed as a means to assess
the quality and record quality grades and descriptions of
effect for each outcome across studies, as well as the quality
grades and description of net benefits or harms of the
intervention or comparator across studies. These profiles aim
to make the evidence synthesis process transparent. However,
since no treatment or non-treatment topic had more than
one study in a summary table for which the quality was
graded, no evidence profiles were generated, and the
information in the summary table shows the highest level
of synthesis.
Grading of Quality of Evidence for Outcomes of Individual
Studies
Methodological quality. Methodological quality (internal
validity) refers to the design, conduct, and reporting of
outcomes of a clinical study. A previously devised three-level
classification system for quality assessment was used to grade
the overall study quality and quality of all relevant outcomes in
the study (Table 39). Variations of this system have been used
in most KDOQI and all KDIGO guidelines and have been
recommended for the US Agency for Healthcare Research and
Quality Evidence-based Practice Center program.722
Each study was given an overall quality grade on the basis
of its design, methodology (randomization, allocation,
blinding, definition of outcomes, appropriate use of statis-
tical methods, etc.), conduct (drop-out percentage, outcome
assessment methodologies, etc.), and reporting (internal
consistency, clarity, thoroughness, and precision, etc.). Each
reported outcome was then evaluated and given an individual
grade depending on the quality of reporting and methodo-
logical issues specific to that outcome. However, the quality
grade of an individual outcome could not exceed the quality
grade for the overall study.
Grading the Quality of Evidence and the Strength of
Guideline Recommendations
A structured approach, based on the GRADE approach,723–725
was used to grade the quality of the overall evidence and the
strength of recommendations for each topic. This grading
scheme-with two levels for the strength of a recommendation
together with four levels of grading for the quality of the
evidence, as well as the option of an ungraded statement
for general guidance-was adopted by the KDIGO Board in
December 2008.
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The strength of a recommendation indicates the extent to
which one can be confident that adherence to the
recommendation will do more good than harm. The quality
of a body of evidence refers to the extent to which our
confidence in an estimate of effect is sufficient to support a
particular recommendation.724 The process of transparently
grading evidence and recommendations for treatment topics
is described below in further detail. However, the approach
had to be adapted for the main topics of the KDIGO CKD
guideline because they were not treatment-related topics.
Grading the Quality of Evidence for Each Outcome Across
Studies
Following the GRADE approach, the quality of a body of
evidence pertaining to a particular outcome of interest was
initially categorized on the basis of study design (Table 40).
For questions of interventions, the initial quality grade was
high if the body of evidence consisted of RCTs, low if it
consisted of observational studies, and very low if it consisted
of studies of other designs. For questions of interventions, the
Work Group decided to use only RCTs. The grade for the
quality of evidence for each intervention–outcome pair was
then lowered if there were serious limitations to the
methodological quality of the aggregate of studies, if there
was thought to be a high likelihood of bias, if there were
important inconsistencies in the results across studies, if there
was uncertainty about the directness of evidence (including
limited applicability of the findings to the population of
interest), if the data were sparse (for example if there was
only one study or if the results include just a few events or
observations and were uninformative) or imprecise (for
example the CI spans a range greater than 1 or confidence
limits are o0.5 to 42.0). The final grade for the quality of
the evidence for an intervention–outcome pair was then
assigned as high, moderate, low, or very low (Table 40).
Grading the Overall Quality of Evidence
The quality of the overall body of evidence was then
determined on the basis of the quality grades for all
Table 38 | Literature yield of primary articles for all topics
Topic
Systematic
review
performed Search dates Search terms
Articles
retrieved
Articles
with full
text
screened
Articles
used in
tables
Non-treatment topics
Prediction equations for eGFR Y MEDLINE search from 2006 until
2011, with an update in June 2011
‘‘kidney,’’ and ‘‘prediction,’’
‘‘equation,’’ ‘‘formula,’’ or
‘‘regression analysis’’
2921 86 15
Prediction equations for risk of
kidney failure or death
N nd nd 10* 10 2
Risk from gadolinium for
nephrogenic fibrosing
dermopathy
Y MEDLINE search from 1996 until
2011 was run in March 2011
‘‘kidney,’’ and ‘‘gadolinium,’’
‘‘nephrogenic fibrosing
dermopathy,’’ or ‘‘nephrogenic
systemic fibrosis,’’ and systematic
review
1w 0 0
Risk for nephropathy from
phosphate-containing bowel
preparations
N MEDLINE search for recent (2008-
2011) narrative reviews was run in
March 2011
‘‘Phosphate nephropathy’’ 2 2 2
Treatment topics
Treatment with bicarbonate Y MEDLINE search from 2005 until
2011, with an update in May 2011
‘‘randomized controlled trial,’’ and
‘‘kidney,’’ or ‘‘metabolic acidosis,’’
and ‘‘bicarbonate’’
3981 6 1
Treatment with allopurinol Y MEDLINE search from 1996 until
2011, with an update in May 2011
‘‘randomized controlled trial,’’ and
‘‘kidney,’’ and ‘‘allopurinol’’
393 4 1
Earlier versus later initiation of
RRT in CKD
N nd nd 8z 8 1
Treatment with protein
restriction
Y Three Cochrane systematic reviews
were identified and used instead of
a de novo systematic review.
MEDLINE search from 1996-2011,
with an update in March 2011
‘‘randomized controlled trial,’’ and
‘‘kidney,’’ and ‘‘diet, protein-
restricted’’
561 1 1
Abbreviations: CKD, chronic kidney disease; eGFR, estimated GFR; nd, not done; RRT, renal replacement therapy.
*References were provided by Work Group members.
wSystematic review provided to Work Group members.
zReferences were provided by Work Group members.
Table 39 | Classification of study quality
Good
quality
Low risk of bias and no obvious reporting errors, complete
reporting of data. Must be prospective. If study of
intervention, must be randomized controlled study.
Fair
quality
Moderate risk of bias, but problems with study or paper are
unlikely to cause major bias. If study of intervention, must be
prospective.
Poor
quality
High risk of bias or cannot exclude possible significant biases.
Poor methods, incomplete data, reporting errors. Prospective
or retrospective.
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outcomes of interest, taking into account explicit judgments
about the relative importance of each outcome. The resulting
four final categories for the quality of overall evidence were
A, B, C, and D (Table 41).
Assessment of the Net Health Benefit Across All Important
Clinical Outcomes
The net health benefit was determined on the basis of the
anticipated balance of benefits and harms across all clinically
important outcomes (Table 42). The assessment of net
benefit also involved the judgment of the Work Group and
the ERT.
Grading the Strength of the Recommendations
The strength of a recommendation is graded as level 1 or
level 2. Table 43 shows the KDIGO nomenclature for grading
the strength of a recommendation and the implications of
each level for patients, clinicians, and policy makers. Recom-
mendations can be for or against doing something. Table 44
shows that the strength of a recommendation is determined
not only by the quality of the evidence, but also by other,
often complex judgments regarding the size of the net
medical benefit, values and preferences, and costs. Formal
decision analyses including cost analysis were not conducted.
Ungraded Statements
This category was designed to allow the Work Group to issue
general advice. Typically an ungraded statement meets the
following criteria: it provides guidance that is based on
common sense, it provides reminders of the obvious, and it is
not sufficiently specific to allow for application of evidence to
the issue and therefore it is not based on systematic evidence
review. The GRADE system is best suited to evaluate evidence
on comparative effectiveness. Some of our most important
guideline topics involve diagnosis and staging within CKD,
about which the Work Group chose to provide ungraded
statements. These statements are indirectly supported by
evidence on risk relationships and are the consensus of the
Work Group. Thus, we believe that ungraded statements
should not be viewed as weaker than graded recommendations.
Table 40 | GRADE system for grading quality of evidence
Step 1: Starting grade for
quality of evidence based
on study design Step 2: Reduce grade Step 3: Raise grade Final grade for quality of evidence and definition
Randomized trials = High Study quality
-1 level if serious limitations
-2 levels if very serious limitations
Consistency
-1 level if important inconsistency
Directness
-1 level if some uncertainty
-2 levels if major uncertainty
Other:
-1 level if sparse or imprecise datac
-1 level if high probability of
reporting bias
Strength of association
+1 level is stronga, no plausible
confounders
+2 levels if very strongb, no major
threats to validity
Other
+1 level if evidence of a
dose-response gradient
+1 level if all residual plausible
confounders would have
reduced the observed effect
High = Further research is unlikely to change confidence
in the estimate of the effect
Observational study = Low
Moderate = Further research is likely to have an
important impact on confidence in the estimate of effect,
and may change the estimate
Low = Further research is very likely to have an important
impact on confidence in the estimate and may change
the estimate
Any other evidence = Very
low
Very low = Any estimate of effect is very uncertain
Abbreviation: GRADE, Grading of Recommendations Assessment, Development, and Evaluation.
aStrong evidence of association is defined as ‘significant relative risk of42 (o0.5)’ based on consistent evidence from two or more observational studies, with no plausible
confounders.
bVery strong evidence of association is defined as ‘significant relative risk of 45 (o0.2)’ based on direct evidence with no major threats to validity.
cSparse if there was only one study or if the results include just a few events or observations and were uninformative. Imprecise if the confidence interval spans a range
greater than 1 or confidence limits are o0.5 to 42.0
Adapted by permission from Macmillan Publishers Ltd: Kidney International. Uhlig K, Macleod A, Craig J et al.725 Grading evidence and recommendations for clinical practice
guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058–2065; accessed http://www.nature.com/
ki/journal/v70/n12/pdf/5001875a.pdf
Table 41 | Final grade for overall quality of evidence
Grade
Quality of
evidence Meaning
A High We are confident that the true effect lies close to that of
the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially
different.
C Low The true effect may be substantially different from the
estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will be
far from the truth.
Table 42 | Balance of benefits and harm
When there was evidence to determine the balance of medical benefits
and harm of an intervention to a patient, conclusions were categorized as
follows:
K For statistically significant benefit/harm, report as ‘benefit [or harm]
of drug X’.
K For non-statistically significant benefit/harm, report as ‘possible
benefit [or harm] of drug X’.
K In instances where studies are inconsistent, report as ‘possible
benefit [or harm] of drug X’.
K ‘No difference’ can only be reported if a study is not imprecise.
K ‘Insufficient evidence’ is reported if imprecision is a factor.
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Table 43 | KDIGO nomenclature and description for grading recommendations
Implications
Grade* Patients Clinicians Policy
Level 1
‘We recommend’
Most people in your situation would
want the recommended course of action
and only a small proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be evaluated as
a candidate for developing a policy or a
performance measure.
Level 2
‘We suggest’
The majority of people in your situation
would want the recommended course of
action, but many would not.
Different choices will be appropriate for
different patients. Each patient needs help
to arrive at a management decision
consistent with her or his values and
preferences.
The recommendation is likely to require
substantial debate and involvement of
stakeholders before policy can be
determined.
Abbreviation: KDIGO, Kidney Disease: Improving Global Outcomes.
*The additional category ‘‘Not Graded’’ was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Table 44 | Determinants of strength of recommendation
Factor Comment
Balance between desirable and
undesirable effects
The larger the difference between the desirable and undesirable effects, the more likely a strong recommendation
is warranted. The narrower the gradient, the more likely a weak recommendation is warranted.
Quality of the evidence The higher the quality of evidence, the more likely a strong recommendation is warranted.
Values and preferences The more variability in values and preferences, or more uncertainty in values and preferences, the more likely a
weak recommendation is warranted.
Costs (resource allocation) The higher the costs of an intervention—that is, the more resources consumed—the less likely a strong
recommendation is warranted.
Reproduced from Going from evidence to recommendations. Guyatt GH, Oxman AD, Kunz R, et al.724 BMJ 336: 1049-1051, 2008 with permission from BMJ Publishing Group
Ltd.; accessed http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376019/pdf/bmj-336-7652-analysis-01049.pdf
Table 45 | The Conference on Guideline Standardization727 checklist for reporting clinical practice guidelines
Topic Description Discussed in KDIGO CKD Guideline
1. Overview material Provide a structured abstract that includes the
guideline’s release date, status (original, revised,
updated), and print and electronic sources.
Abstract and Methods for Guideline Development.
2. Focus Describe the primary disease/condition and
intervention/service/technology that the
guideline addresses. Indicate any alternative
preventative, diagnostic, or therapeutic
interventions that were considered during
development.
Evaluation and management of adults and children with CKD.
3. Goal Describe the goal that following the guideline is
expected to achieve, including the rationale for
development of a guideline on this topic.
This clinical practice guideline is intended to assist the practitioner
caring for patients with CKD and to prevent deaths, cardiovascular
disease events and progression to kidney failure while optimizing
patients’ quality of life.
4. User/setting Describe the intended users of the guideline (e.g.,
provider types, patients) and the settings in which
the guideline is intended to be used.
Providers: Nephrologists (adult and pediatric), Dialysis providers
(including nurses), Internists, and Pediatricians.
Patients: Adult and pediatric individuals at risk for or with CKD.
Policy Makers: Those in related health fields.
5. Target population Describe the patient population eligible for
guideline recommendations and list any exclusion
criteria.
Individuals at risk for or with CKD.
6. Developer Identify the organization(s) responsible for
guideline development and the names/
credentials/potential conflicts of interest of
individuals involved in the guideline’s
development.
Organization: KDIGO.
Refer to Biographic and Disclosure Information section.
7. Funding
source/sponsor
Identify the funding source/sponsor and describe
its role in developing and/or reporting the
guideline. Disclose potential conflict of interest.
KDIGO is supported by the following consortium of sponsors:
Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-
Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole
Food Company, Fresenius Medical Care, Genzyme, Hoffmann-
LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO—The Organization
for Transplant Professionals, NKF-Board of Directors, Novartis,
Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik
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Table 45 | Continued
Topic Description Discussed in KDIGO CKD Guideline
Foundation, Shire, Takeda Pharmaceutical, Transwestern
Commercial Services, Vifor Pharma, and Wyeth.
No funding is accepted for the development or reporting of specific
guidelines.
All stakeholders could participate in open review.
8. Evidence collection Describe the methods used to search the scientific
literature, including the range of dates and
databases searched, and criteria applied to filter
the retrieved evidence.
Screening criteria are outlined in the methods chapter. The search
was updated through June 2011 and supplemented by articles
identified by Work Group members through November 2012.
We also searched for pertinent existing guidelines and systematic
reviews.
9. Recommendation
grading criteria
Describe the criteria used to rate the quality of
evidence that supports the recommendations and
the system for describing the strength of the
recommendations. Recommendation strength
communicates the importance of adherence to a
recommendation and is based on both the quality
of the evidence and the magnitude of anticipated
benefits and harms.
Quality of individual studies was graded in a three-tiered grading
system (see Table 39). Quality of evidence (Table 40) was graded
following the GRADE approach. Strength of the recommendation
was graded in a two-level grading system which was adapted from
GRADE for KDIGO with the quality of overall evidence graded on a
four-tiered system (Tables 41 and 43).
The Work Group could provide general guidance in ungraded
statements.
10. Method for
synthesizing
evidence
Describe how evidence was used to create
recommendations, e.g., evidence tables, meta-
analysis, decision analysis.
For systematic review topics, summary tables and evidence profiles
were generated.
For recommendations on treatment interventions, the steps
outlined by GRADE were followed.
11. Prerelease review Describe how the guideline developer reviewed
and/or tested the guidelines prior to release.
The guideline had undergone internal review by the KDIGO Board of
Directors in January 2012 and external review in May 2012. Public
review comments were compiled and fed back to the Work Group,
which considered comments in its revision of the guideline.
12. Update plan State whether or not there is a plan to update the
guideline and, if applicable, expiration date for
this version of the guideline.
There is no date set for updating this entire guideline. The need for
updating of the guideline will depend on the publication of new
evidence that would change the quality of the evidence or the
estimates for the benefits and harms. Results from registered
ongoing studies and other publications will be reviewed periodically
to evaluate their potential to impact on the recommendations in
this guideline. Specific sections may be updated separately from the
entire guideline within the next 3–5 years depending on the
evidence base.
13. Definitions Define unfamiliar terms and those critical to
correct application of the guideline that might be
subject to misinterpretation.
Acronyms and Abbreviations.
14. Recommendations
and rationale
State the recommended action precisely and the
specific circumstances under which to perform it.
Justify each recommendation by describing the
linkage between the recommendation and its
supporting evidence. Indicate the quality of
evidence and the recommendation strength,
based on the criteria described in Topic 9.
Each guideline chapter contains recommendations for evaluation
and management of CKD patients. Each recommendation builds on
a supporting rationale with evidence tables if available. The strength
of the recommendation and the quality of evidence are provided in
parenthesis within each recommendation.
15. Potential benefits
and harm
Describe anticipated benefits and potential risks
associated with implementation of guideline
recommendations.
The benefits and harm for each comparison of interventions is
provided in summary tables and summarized in evidence profiles.
The estimated balance between potential benefits and harm was
considered when formulating the recommendations.
16. Patient preferences Describe the role of patient preferences when a
recommendation involves a substantial element
of personal choice or values.
Many recommendations are ungraded which indicates a greater
need to help each patient arrive at a management decision
consistent with her or his values and preferences.
17. Algorithm Provide (when appropriate) a graphical
description of the stages and decisions in clinical
care described by the guideline.
Algorithm for proteinuria/albuminuria testing in Chapter 1.
18. Implementation
considerations
Describe anticipated barriers to application of the
recommendations. Provide reference to any
auxiliary documents for providers or patients that
are intended to facilitate implementation. Suggest
review criteria for measuring changes in care
when the guideline is implemented.
These recommendations are global and the Work Group
acknowledges the importance of local application. Review criteria
were not suggested because implementation with prioritization and
development of review criteria must proceed locally. Furthermore,
most recommendations are discretionary, requiring substantial
discussion among stakeholders before they can be considered for
adoptions as review criteria.
Suggestions were provided for future research.
Abbreviations: CKD, chronic kidney disease; COGS, Conference on Guideline Standardization; GRADE, Grading of Recommendations Assessment, Development, and
Evaluation; KDIGO, Kidney Disease: Improving Global Outcomes; NKF, National Kidney Foundation.
Adapted with permission from Shiffman RN, Shekelle P, Overhage JM, et al.727 Standardized reporting of clinical practice guidelines: a proposal from the Conference on
Guideline Standardization. Ann Intern Med 2003; 139(6): 493-498; accessed http://annals.org/data/Journals/AIM/20049/0000605-200309160-00013.pdf
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The Work Group took on the primary role of writing the
recommendations and rationale statements and retained final
responsibility for the content of the guideline statements and
the accompanying narrative. The ERT reviewed draft
recommendations and grades for consistency with the
conclusions of the evidence review.
Format for Guideline Recommendations
Each chapter contains one or more specific recommen-
dations. Within each recommendation, the strength of
recommendation is indicated as level 1 or level 2 and the
quality of the supporting evidence is shown as A, B, C or D.
The recommendation statements and grades are followed by
the rationale and clarification of the wording of the
statement, a brief background with relevant definitions of
terms, and then a chain of logic which summarizes the key
points of the evidence base and the judgments supporting the
recommendation. Some sections also contain research
recommendations in variable degrees of detail, suggesting
future research to resolve current uncertainties.
Limitations of Approach
Although the literature searches were intended to be
comprehensive, they were not exhaustive. MEDLINE was
the only database searched. Hand searches of journals were
not performed, and review articles and textbook chapters
were not systematically searched. However, important studies
known to domain experts that were missed by the electronic
literature searches were added to the retrieved articles and
reviewed by the Work Group.
Summary of the Review Process
Several tools and checklists have been developed to assess the
quality of the methodological process for systematic review and
guideline development. These include the Appraisal of Guidelines
for Research and Evaluation (AGREE) criteria,726 the Conference
on Guideline Standardization (COGS) checklist,727 and the
Institute of Medicine’s recent Standards for Systematic Reviews728
and Clinical Practice Guidelines We Can Trust.729 Table 45 and
Appendix 1 demonstrate the level of concurrence to the COGS
criteria and the Institute of Medicine standards, respectively.
SUPPLEMENTARY MATERIAL
Supplemental Table 1: Search strategy.
Appendix 1: Concurrence with Institute of Medicine standards for
systematic reviews and for guidelines.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/ckd.php
Kidney International Supplements (2013) 3, 120–127 127
methods fo r gu ide l ine deve lopment
